JP2013527162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527162A5 JP2013527162A5 JP2013506723A JP2013506723A JP2013527162A5 JP 2013527162 A5 JP2013527162 A5 JP 2013527162A5 JP 2013506723 A JP2013506723 A JP 2013506723A JP 2013506723 A JP2013506723 A JP 2013506723A JP 2013527162 A5 JP2013527162 A5 JP 2013527162A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- disease
- compound according
- disorders
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000001931 aliphatic group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 10
- 206010012289 Dementia Diseases 0.000 claims 8
- 208000002705 Glucose Intolerance Diseases 0.000 claims 8
- 208000010877 cognitive disease Diseases 0.000 claims 8
- 208000010125 myocardial infarction Diseases 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 208000027534 Emotional disease Diseases 0.000 claims 6
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims 4
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 claims 3
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- -1 pyrrolidino, piperidino, piperazino, morpholino Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010065941 Central obesity Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000014311 Cushing syndrome Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 208000016222 Pancreatic disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 2
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000025748 atypical depressive disease Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000003820 β-cell dysfunction Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32945310P | 2010-04-29 | 2010-04-29 | |
| US61/329,453 | 2010-04-29 | ||
| PCT/GB2011/000345 WO2011135276A1 (en) | 2010-04-29 | 2011-03-10 | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527162A JP2013527162A (ja) | 2013-06-27 |
| JP2013527162A5 true JP2013527162A5 (https=) | 2014-03-27 |
| JP5899202B2 JP5899202B2 (ja) | 2016-04-06 |
Family
ID=43880967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013506723A Active JP5899202B2 (ja) | 2010-04-29 | 2011-03-10 | １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9365564B2 (https=) |
| EP (1) | EP2563780B1 (https=) |
| JP (1) | JP5899202B2 (https=) |
| KR (1) | KR101714820B1 (https=) |
| CN (1) | CN102947295B (https=) |
| AU (1) | AU2011247116B2 (https=) |
| BR (1) | BR112012027640B1 (https=) |
| CA (1) | CA2796297C (https=) |
| DK (1) | DK2563780T3 (https=) |
| ES (1) | ES2543692T3 (https=) |
| IL (1) | IL222417A (https=) |
| MX (1) | MX344142B (https=) |
| RU (1) | RU2593753C2 (https=) |
| WO (1) | WO2011135276A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0724251D0 (en) | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
| GB0804685D0 (en) | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
| EP2477983B1 (en) | 2009-09-16 | 2015-04-15 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use |
| WO2011135276A1 (en) | 2010-04-29 | 2011-11-03 | The University Of Edinburgh | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1 |
| FR2993563B1 (fr) * | 2012-07-20 | 2015-12-18 | Metabrain Res | Derives de thiophenes utiles dans le traitement du diabete |
| WO2015131773A1 (zh) * | 2014-03-06 | 2015-09-11 | 上海海雁医药科技有限公司 | 作为食欲素受体拮抗剂的哌啶衍生物 |
| FR3035326B1 (fr) * | 2015-04-21 | 2017-05-12 | Pf Medicament | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| CN104961698A (zh) * | 2015-07-13 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 末端硝基取代的三氮唑亚砜类化合物、其制备方法及其用途 |
| CN104974080A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途 |
| CN104945315A (zh) * | 2015-07-19 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | 一类硝基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
| CN104961677A (zh) * | 2015-07-19 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 一类腈基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
| EP3373920A4 (en) | 2015-11-13 | 2019-07-17 | Pietro Paolo Sanna | METHOD AND COMPOSITIONS FOR TREATING ALCOHOL CONSUMPTION MALFUNCTIONS |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| TW202523658A (zh) * | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| MX2022003845A (es) * | 2019-09-30 | 2022-06-22 | Actinogen Medical Ltd | Tratamientos cognitivos medicinales. |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2022094668A1 (en) * | 2020-11-06 | 2022-05-12 | Actinogen Medical Limited | Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof |
| JP2023550654A (ja) * | 2020-11-25 | 2023-12-04 | セージ セラピューティクス， インコーポレイテッド | 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物 |
| JP2025519558A (ja) * | 2022-06-10 | 2025-06-26 | アクチノゲン メディカル リミテッド | 抗うつ薬抵抗性対象の治療 |
| CN115073422A (zh) * | 2022-07-28 | 2022-09-20 | 成都普瑞熙药业有限公司 | 一种制备4-(1-甲基-1h-吡唑-5-基)哌啶及其盐的方法 |
| CN120153257A (zh) * | 2022-10-07 | 2025-06-13 | 射线质医疗有限公司 | 用于11β-HSD1抑制剂治疗的受试者选择 |
| CN120957989A (zh) * | 2023-03-02 | 2025-11-14 | 射线质医疗有限公司 | 用于制备氮杂双环杂芳基化合物的流动化学工艺 |
| WO2025073002A1 (en) * | 2023-10-03 | 2025-04-10 | Actinogen Medical Limited | Tablet formulation |
| GB202408335D0 (en) | 2024-06-11 | 2024-07-24 | Astrazeneca Ab | Therapies for wound treatment |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087631A (en) | 1990-12-18 | 1992-02-11 | Glaxo Inc. | Oxathi(SIV)azol-5-one compounds |
| AR011913A1 (es) | 1997-03-06 | 2000-09-13 | Yamano Masaki | Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos. |
| US6303593B1 (en) | 1999-03-02 | 2001-10-16 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
| AU2002353716A1 (en) | 2001-11-22 | 2003-06-10 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| GB0325745D0 (en) | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| GB0326029D0 (en) | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| RU2006146608A (ru) | 2004-06-09 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ |
| EP1894919B1 (en) | 2005-06-07 | 2012-03-28 | Shionogi & Co., Ltd. | Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity |
| CN101243074A (zh) * | 2005-06-08 | 2008-08-13 | 日本烟草产业株式会社 | 杂环化合物 |
| EP1889842A4 (en) | 2005-06-08 | 2009-07-29 | Japan Tobacco Inc | HETEROCYCLIC CONNECTION |
| US7803806B2 (en) | 2005-11-03 | 2010-09-28 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
| BRPI0710479A2 (pt) | 2006-01-18 | 2012-08-14 | Hoffmann La Roche | composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica. |
| CN101484424B (zh) | 2006-02-28 | 2014-05-14 | 达特神经科学(开曼)有限公司 | 治疗化合物 |
| UA95480C2 (uk) | 2006-06-08 | 2011-08-10 | Елі Ліллі Енд Компані | Заміщені карбоксаміди |
| TW200811170A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
| US7666888B2 (en) | 2006-07-20 | 2010-02-23 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 |
| JP5529743B2 (ja) * | 2007-11-05 | 2014-06-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 選択的１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤としての７−アザインドール誘導体 |
| GB0724251D0 (en) * | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
| US20100022590A1 (en) | 2008-01-17 | 2010-01-28 | Biovitrum Ab (Publ.) | Novel compounds |
| GB0804685D0 (en) * | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
| CA2735204C (en) * | 2008-08-25 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| EP2443113A1 (en) | 2009-06-15 | 2012-04-25 | The University Of Edinburgh | Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders |
| EP2477983B1 (en) | 2009-09-16 | 2015-04-15 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use |
| WO2011135276A1 (en) | 2010-04-29 | 2011-11-03 | The University Of Edinburgh | 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1 |
-
2011
- 2011-03-10 WO PCT/GB2011/000345 patent/WO2011135276A1/en not_active Ceased
- 2011-03-10 MX MX2012012413A patent/MX344142B/es active IP Right Grant
- 2011-03-10 JP JP2013506723A patent/JP5899202B2/ja active Active
- 2011-03-10 BR BR112012027640-9A patent/BR112012027640B1/pt active IP Right Grant
- 2011-03-10 RU RU2012143502/04A patent/RU2593753C2/ru active
- 2011-03-10 DK DK11709770.9T patent/DK2563780T3/en active
- 2011-03-10 CN CN201180031564.6A patent/CN102947295B/zh active Active
- 2011-03-10 AU AU2011247116A patent/AU2011247116B2/en active Active
- 2011-03-10 KR KR1020127028597A patent/KR101714820B1/ko active Active
- 2011-03-10 EP EP11709770.9A patent/EP2563780B1/en active Active
- 2011-03-10 CA CA2796297A patent/CA2796297C/en active Active
- 2011-03-10 ES ES11709770.9T patent/ES2543692T3/es active Active
- 2011-03-10 US US13/642,963 patent/US9365564B2/en active Active
-
2012
- 2012-10-14 IL IL222417A patent/IL222417A/en active IP Right Grant
-
2016
- 2016-05-13 US US15/154,254 patent/US9834549B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527162A5 (https=) | ||
| JP2013504613A5 (https=) | ||
| RU2012143502A (ru) | Двузамещенные метаноны в качестве ингибиторов 11 (вета)-hsd1 | |
| JP2011513476A5 (https=) | ||
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| DE60311980T2 (de) | Histondeacetylase-hemmer | |
| TWI767410B (zh) | 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途 | |
| JP6180509B2 (ja) | 新規化合物 | |
| EP4086256A1 (en) | Small molecule inhibitors of the jak family of kinases | |
| US20050171103A1 (en) | Benzamide derivatives useful as histone deacetylase inhibitors | |
| JP2018534326A5 (https=) | ||
| IL302997B2 (en) | Purine inhibitors | |
| JP2015514794A5 (https=) | ||
| CA2972112C (en) | Pyrimidone compounds used as lp-pla2 inhibitors and pharmaceutical compositions thereof | |
| JP5124471B2 (ja) | 置換二環式ピリミドン誘導体 | |
| JP2008525363A (ja) | プロスタグランジン媒介疾患治療のためのピリジン化合物 | |
| JP5197584B2 (ja) | 含窒素芳香族６員環誘導体並びにそれらを含む医薬 | |
| JP2024525561A (ja) | 化合物、組成物及び方法 | |
| JP6100755B2 (ja) | （２−ヘテロアリールアミノ）コハク酸誘導体 | |
| JP5366803B2 (ja) | 脳梗塞治療剤 | |
| WO2014027199A1 (en) | Fak and flt3 inhibitors | |
| CN116134022B (zh) | Atr抑制剂和其用途 | |
| CN101137644A (zh) | 7-（2-（4-（3-三氟甲基-苯基）-1,2,3,6-四氢-吡啶-1-基）乙基）异喹啉苯磺酸盐、它的制备与治疗用途 | |
| US20080119451A1 (en) | Novel Benzamide Derivatives | |
| JP2007509039A (ja) | シクロペンテン化合物 |